Canada, UK weighing Lecanemab as early Alzheimer’s treatment
Eisai and Biogen are seeking approval in Canada and the U.K. for lecanemab to treat early Alzheimer’s disease. It’s available under the name Leqembi in the U.S. Health Canada has accepted the application for review, while the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA)…